Lazard Asset Management
OMGA

Lazard Asset Management’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Lazard Asset Management’s Portfolio OMGA Stock Details OMGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,797
Closed -$3K – 2515
2023
Q3 		$3K Buy
1,797
+83
+5% +$332 ﹤0.01% 2193
2023
Q2 		$9K Buy
1,714
+72
+4% +$563 ﹤0.01% 2192
2023
Q1 		$9K Buy
1,642
+303
+23% +$2.11K ﹤0.01% 2138
2022
Q4 		$7K Buy
+1,339
New +$7.51K ﹤0.01% 2241

Other funds holding OMGA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Lazard Asset Management's OMGA Position: Q4 2023 in Review

Lazard Asset Management sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q4 2023, closing a stake of 1,797 shares — an estimated $3K sold.

Lazard Asset Management first reported a position in OMGA in Q4 2022 and held it in 4 quarters. The position peaked at $9K in Q2 2023. 63 funds tracked by Wall St. Rank hold OMGA as of Q4 2023.

  • Lazard Asset Management reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Lazard Asset Management sold 1,797 Omega Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $3K.
  • Lazard Asset Management first reported a position in Omega Therapeutics, Inc. Common Stock in Q4 2022 and held it in 4 quarters.
  • Lazard Asset Management's Omega Therapeutics, Inc. Common Stock position peaked at $9K in Q2 2023.
  • 63 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Lazard Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.